surpass cvot tirzepatide results 💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What An Observational Study of Cardiovascular

This article explores what clinical trial data reveal about retatrutide's gastrointestinal side effects, how acid reflux symptoms can be managed, and when to seek medical advice

In parallel, Reta also exerts favorable effects on lipid metabolism

The AASLD now recommends identifying MASH candidates using non-invasive tests such as vibration-controlled transient elastography, MR elastography, or enhanced liver fibrosis score rather than liver biopsy, which lowers the barrier to diagnosis and treatment

If you experience, or think you are experiencing, any of the below symptoms, you should seek immediate medical attention